Higgons John Duncan 4
4 · Jounce Therapeutics, Inc. · Filed Jun 13, 2019
Insider Transaction Report
Form 4
Higgons John Duncan
Director
Transactions
- Award
Stock Option (Right to Buy)
2019-06-12+15,700→ 15,700 totalExercise: $4.46Exp: 2029-06-12→ Common Stock (15,700 underlying)
Footnotes (1)
- [F1]The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2020 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors.